Clinical research of EGFR inhibitors and related dermatologic toxicities.

Roman Perez-Soler, Eric Van Cutsem

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

An acneiform-like skin toxicity is commonly observed in patients with solid tumors treated with epidermal growth factor receptor inhibitors (EGFRIs). This symptomatic rash is related to epidermal growth factor receptor (EGFR) inhibition in the skin. A positive relation between the presence and severity of treatment-related rash and survival has been consistently observed with all EGFRIs approved for clinical use. These findings suggest that rash may be a useful surrogate marker of successful EGFR inhibition and clinical benefit and therefore of possible use in identifying patients most likely to benefit from therapy, as well as to guide dose adjustments. Increasing drug dose until skin toxicity appears is being studied. Further studies are needed to thoroughly evaluate the value of skin toxicity as a surrogate marker for clinical benefit. Current treatments of the skin toxicity are empirical and oriented toward mitigating symptoms and not validated by well-controlled clinical trials. Rational treatments based on the biological mechanisms of the skin toxicity must be developed and tested in well-controlled clinical trials.

Original languageEnglish (US)
Pages (from-to)10-16
Number of pages7
JournalOncology (Williston Park, N.Y.)
Volume21
Issue number11 Suppl 5
StatePublished - Oct 2007

Fingerprint

Epidermal Growth Factor Receptor
Skin
Exanthema
Research
Controlled Clinical Trials
Biomarkers
Therapeutics
Survival
Pharmaceutical Preparations
Neoplasms

ASJC Scopus subject areas

  • Oncology

Cite this

Clinical research of EGFR inhibitors and related dermatologic toxicities. / Perez-Soler, Roman; Van Cutsem, Eric.

In: Oncology (Williston Park, N.Y.), Vol. 21, No. 11 Suppl 5, 10.2007, p. 10-16.

Research output: Contribution to journalArticle

@article{05967228170641ce962b2262c8e2451e,
title = "Clinical research of EGFR inhibitors and related dermatologic toxicities.",
abstract = "An acneiform-like skin toxicity is commonly observed in patients with solid tumors treated with epidermal growth factor receptor inhibitors (EGFRIs). This symptomatic rash is related to epidermal growth factor receptor (EGFR) inhibition in the skin. A positive relation between the presence and severity of treatment-related rash and survival has been consistently observed with all EGFRIs approved for clinical use. These findings suggest that rash may be a useful surrogate marker of successful EGFR inhibition and clinical benefit and therefore of possible use in identifying patients most likely to benefit from therapy, as well as to guide dose adjustments. Increasing drug dose until skin toxicity appears is being studied. Further studies are needed to thoroughly evaluate the value of skin toxicity as a surrogate marker for clinical benefit. Current treatments of the skin toxicity are empirical and oriented toward mitigating symptoms and not validated by well-controlled clinical trials. Rational treatments based on the biological mechanisms of the skin toxicity must be developed and tested in well-controlled clinical trials.",
author = "Roman Perez-Soler and {Van Cutsem}, Eric",
year = "2007",
month = "10",
language = "English (US)",
volume = "21",
pages = "10--16",
journal = "Oncology",
issn = "0890-9091",
publisher = "UBM Medica Healthcare Publications",
number = "11 Suppl 5",

}

TY - JOUR

T1 - Clinical research of EGFR inhibitors and related dermatologic toxicities.

AU - Perez-Soler, Roman

AU - Van Cutsem, Eric

PY - 2007/10

Y1 - 2007/10

N2 - An acneiform-like skin toxicity is commonly observed in patients with solid tumors treated with epidermal growth factor receptor inhibitors (EGFRIs). This symptomatic rash is related to epidermal growth factor receptor (EGFR) inhibition in the skin. A positive relation between the presence and severity of treatment-related rash and survival has been consistently observed with all EGFRIs approved for clinical use. These findings suggest that rash may be a useful surrogate marker of successful EGFR inhibition and clinical benefit and therefore of possible use in identifying patients most likely to benefit from therapy, as well as to guide dose adjustments. Increasing drug dose until skin toxicity appears is being studied. Further studies are needed to thoroughly evaluate the value of skin toxicity as a surrogate marker for clinical benefit. Current treatments of the skin toxicity are empirical and oriented toward mitigating symptoms and not validated by well-controlled clinical trials. Rational treatments based on the biological mechanisms of the skin toxicity must be developed and tested in well-controlled clinical trials.

AB - An acneiform-like skin toxicity is commonly observed in patients with solid tumors treated with epidermal growth factor receptor inhibitors (EGFRIs). This symptomatic rash is related to epidermal growth factor receptor (EGFR) inhibition in the skin. A positive relation between the presence and severity of treatment-related rash and survival has been consistently observed with all EGFRIs approved for clinical use. These findings suggest that rash may be a useful surrogate marker of successful EGFR inhibition and clinical benefit and therefore of possible use in identifying patients most likely to benefit from therapy, as well as to guide dose adjustments. Increasing drug dose until skin toxicity appears is being studied. Further studies are needed to thoroughly evaluate the value of skin toxicity as a surrogate marker for clinical benefit. Current treatments of the skin toxicity are empirical and oriented toward mitigating symptoms and not validated by well-controlled clinical trials. Rational treatments based on the biological mechanisms of the skin toxicity must be developed and tested in well-controlled clinical trials.

UR - http://www.scopus.com/inward/record.url?scp=38549167111&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=38549167111&partnerID=8YFLogxK

M3 - Article

VL - 21

SP - 10

EP - 16

JO - Oncology

JF - Oncology

SN - 0890-9091

IS - 11 Suppl 5

ER -